Evotec Results Presentation Deck

evotec Proteomics approach to targeted protein degradation Development of novel therapies for a broad range of diseases Opportunity to expand and accelerate with AI/ML PAGE 23 Protein degradation partnership extended and expanded Alliance with BMS since 2018 - already proven to be highly productive evotec & & ll Bristol Myers Squibb May 2020 First screening milestone Oct 2020 First project initiation 2018 Upfront US$ 65 m • Potential milestones 2019 > US$ 250 m per project • Double-digit royalties 2020 June 2020 US$ 10 m - Expansion New Mar 2021 Significant double-digit m extension Dec 2020 Second project initiation New June 2021 New protein degradation collaboration in undis- closed therapeutic area 2021 New May 2021 Third project initiation

View entire presentation